Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells

Monday O Ogese1, Lee Faulkner2, Roz E Jenkins2

  • 1Pathology Sciences, Drug Safety and Metabolism, AstraZeneca R&D, Cambridge Science Park, Cambridge CB4 0WG, UK.

Insights

Drug-induced liver injury (DILI) involves T-cells. This study reveals how drug-exposed liver cells signal to immune cells, influencing T-cell responses and potential injury.

Area of Science:

  • Hepatology
  • Immunology
  • Pharmacology

Background:

  • Drug-induced liver injury (DILI) involves T-cell activation.
  • Hepatocyte-immune cell crosstalk is crucial in drug response outcomes.

Purpose of the Study:

  • To profile signals from drug-treated hepatocytes.
  • To characterize the impact of these signals on dendritic cells.

Main Methods:

  • Human hepatocytes exposed to flucloxacillin, amoxicillin, isoniazid, and SMX-NO.
  • Assessed hepatocyte toxicity, cytokine release, and oxidative stress.
  • Dendritic cell phenotype and function analyzed after exposure to hepatocyte supernatants.

Main Results:

  • SMX-NO and flucloxacillin caused hepatocyte toxicity, releasing High-mobility group box 1 protein (HMGB1).
  • HMGB1 stimulated dendritic cell cytokine release and T-cell priming.
  • Distinct cytokine profiles observed in dendritic cells exposed to different drug-treated hepatocyte supernatants.

Conclusions:

  • Identified drug-specific signaling pathways between hepatocytes and immune cells.
  • These pathways may determine if drug exposure leads to immune response and tissue injury.
  • Highlights the role of HMGB1 in mediating immune responses to drug-induced liver injury.